Versigent (NYSE:VGNT) Earns Outperform Rating from BNP Paribas Exane

Key Points

• BNP Paribas Exane reiterated its Outperform rating on Versigent but lowered its price target from $55 to $54, implying about 32% upside from the prior close.
• Analyst sentiment is broadly positive: Versigent has a “Moderate Buy” consensus and an average price target of $55.08. The company also beat quarterly earnings and revenue estimates, reporting adjusted EPS of $1.91 and revenue of $2.45 billion.
• Shares fell to $40.91 on Thursday, while insiders sold 220,000 shares worth about $10.1 million over the past 90 days.

Versigent (NYSE:VGNT - Get Free Report)'s stock had its "outperform" rating reiterated by stock analysts at BNP Paribas Exane in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $54.00 price target on the stock, down from their prior price target of $55.00. BNP Paribas Exane's target price points to a potential upside of 31.98% from the stock's previous close.

A number of other analysts also recently commented on the company. Weiss Ratings upgraded Versigent from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $54.00 target price on shares of Versigent in a research report on Wednesday, August 5th. UBS Group lowered their price objective on Versigent from $58.00 to $55.00 and set a "buy" rating for the company in a report on Thursday, July 9th. Argus raised their target price on shares of Versigent from $50.00 to $54.00 and gave the stock a "buy" rating in a report on Thursday, August 13th. Finally, Oppenheimer set a $50.00 price objective on shares of Versigent in a research report on Tuesday, July 21st. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Versigent currently has a consensus rating of "Moderate Buy" and an average target price of $55.08.

Versigent Stock Performance

NYSE VGNT traded down $1.05 during trading hours on Thursday, hitting $40.91. 340,164 shares of the stock were exchanged, compared to its average volume of 1,520,438. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 7.29. The stock has a 50-day moving average of $45.08 and a 200 day moving average of $42.71. The company has a market cap of $2.90 billion and a price-to-earnings ratio of 21.31. Versigent has a 12-month low of $26.34 and a 12-month high of $50.88.

Versigent (NYSE:VGNT - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.12. The firm had revenue of $2.45 billion during the quarter, compared to analysts' expectations of $2.42 billion. As a group, equities research analysts forecast that Versigent will post 7.23 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Kevin Clark sold 47,761 shares of the firm's stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $44.36, for a total value of $2,118,677.96. Following the completion of the transaction, the director directly owned 27,571 shares of the company's stock, valued at $1,223,049.56. This trade represents a 63.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 220,000 shares of company stock worth $10,065,848 over the last 90 days.

Institutional Investors Weigh In On Versigent

A number of hedge funds and other institutional investors have recently bought and sold shares of VGNT. Salomon & Ludwin LLC increased its position in Versigent by 78.3% during the 3rd quarter. Salomon & Ludwin LLC now owns 708 shares of the company's stock worth $32,000 after buying an additional 311 shares during the period. Signaturefd LLC lifted its position in shares of Versigent by 40.0% during the 3rd quarter. Signaturefd LLC now owns 1,121 shares of the company's stock worth $50,000 after buying an additional 320 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Versigent by 53.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,052 shares of the company's stock valued at $47,000 after purchasing an additional 365 shares in the last quarter. Fortitude Family Office LLC grew its stake in shares of Versigent by 497.1% during the third quarter. Fortitude Family Office LLC now owns 621 shares of the company's stock worth $28,000 after buying an additional 517 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Versigent by 54.8% in the third quarter. GAMMA Investing LLC now owns 2,249 shares of the company's stock valued at $101,000 after purchasing an additional 796 shares during the last quarter.

Trending Headlines about Versigent

Here are the key news stories impacting Versigent this week:

• Positive Sentiment: Q3 revenue was $2.45 billion, up 7.2% year over year, and adjusted EPS of $1.91 beat the $1.79 consensus estimate. Revenue also topped forecasts of $2.42 billion. Versigent Reports Third Quarter 2026 Results
• Positive Sentiment: The company declared a quarterly dividend of $0.13 per share, payable December 17, equivalent to an annualized yield of about 1.2%. Dividend announcement
• Neutral Sentiment: CFO Doug Ostermann is scheduled to speak at the RBC Capital Markets Global Industrials Conference on November 17; the announcement did not include new financial guidance. CFO to Participate in RBC Conference
• Negative Sentiment: Despite the reported sales increase, adjusted net sales growth was approximately 1% year over year. That subdued underlying growth, alongside market pressures discussed on the earnings call, tempers the headline beat and may help explain the stock’s recent weakness. The company reported GAAP diluted EPS of $1.41, below its adjusted EPS figure. Versigent Earnings Call Shows Growth Despite Market Pressures

About Versigent

Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.